News

Cerillo® Announces Partnership with Opentrons to Deliver Automated Microbiome Research Solutions

Cerillo®, a technology company developing advanced research platforms for microbiome studies, today announced a partnership with Opentrons Labworks, Inc., a leading force in lab automation. The collaboration not only grants researchers access to entry-level lab automation but also extends the reach of Cerillo’s comprehensive suite of microbiome research tools, fostering standardization and efficiency in laboratory processes .

Cerillo and Opentrons are automating microbiome research and the discovery of microbiome therapeutics by seamlessly integrating Cerillo’s miniaturized Alto™ and Stratus® microplate readers onto the OT-2 and Flex for deck ELISA and cell growth analysis. This integration enables easy setup of experiments, including bacterial co­culture studies with Cerillo’s Co-culture platform.

According to Eric Mayton, CEO of Cerillo, “The integration of Cerillo’s products with Opentrons’ platforms aligns with our mission to provide accessible, cost effective, user-friendly laboratory tools that efficiently standardize global microbiome research at the bench. Our alignment with Opentrons’ open-source robotics platform sets new standards for industry efficiency.”

Cerillo’s Microbiome Discovery Platform

The Cerillo Microbiome Discovery Platform offers a comprehensive suite of tools to tackle the challenges of microbiome research head-on. This interconnected platform introduces unprecedented efficiencies, elevating data standardization, reproducibility, and analysis of research findings. Cerillo’s innovative platform includes:

Co-Culture Duet System®: Cerillo’s off-the-shelf microbial interaction platform features duets with porous barriers, allowing researchers to physically isolate populations while maintaining fluidic contact. This enables the observation, study, and growth measurement of individual microbial populations alongside others.

Miniaturized Microplate Readers: Cerillo’s compact microplate readers, like the next-generation Alto™, are ten times smaller than standard ones, perfect for monitoring measurements in tight spaces and anaerobic chambers. Alto is also Ideal for ELISA and high-throughput microbial growth curve applications.

Canopy Wireless Accessory Package: Cerillo’s revolutionary SaaS package offers wireless capabilities and robust software analytics so that researchers can experience real-time data visualization, monitoring, and wireless control of their microplate readers and scale their experiments by connecting multiple readers simultaneously.

 

Learn more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and